Navigation Links
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Date:8/19/2007

in

blood Phe level of 236 uM/L (29 percent) compared to a mean increase

of 3 uM/L (3 percent) in the placebo group (p<0.0001). Prior to

treatment, patients in the Kuvan group and placebo group had mean

blood Phe levels of 843 uM/L and 888 uM/L, respectively.

* After six weeks of treatment, 54 percent of patients treated with

Kuvan and 23 percent of patients in the placebo group had a blood

phenylalanine concentration below the recommended 600 uM/L level

(p=0.003).

* Blood phenylalanine concentrations fell by about 200 uM/L after one

week in the Kuvan group, and this reduction persisted for the

remaining five weeks of the study (p<0.0001).

* The type and incidence of adverse events was similar in the Kuvan

and placebo groups. Kuvan was well tolerated and investigators

reported that no serious adverse event occurred.

About Kuvan

Kuvan is an investigational oral small molecule therapeutic for the treatment of PKU. The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. Clinical data suggest that treatment with Kuvan results in significant reductions in blood Phe levels in BH4-responsive patients. It also may enable some patients to minimize or eliminate highly-restrictive dietary constraints by increasing Phe tolerance levels. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). If approved, it will receive seven years of market exclusi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Research and ... Report of Pralmorelin" report to their offering. ... providing comprehensive data on Pralmorelin globally and regionally ( ... North America , Latin America ... Pralmorelin This report focuses on three primary areas; ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... -- Glades Drugs, an independent pharmacy chain based out of ... into a new corporate headquarters in Lake Worth, ... and state of the art lab. With this expansion Glades ... the new facility. The newly acquired office ... chain,s corporate headquarters and closed door pharmacy, and is in ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Loss of ... help explain why many seniors have trouble falling and ... patients, sleep disruption can be especially severe and often ... researchers. The investigators analyzed data from the Rush ... who enrolled at age 65 and are being followed ...
(Date:8/20/2014)... The Board of Directors of top ... is pleased to announce the expansion of its ... and the surrounding region. In support of this ... AIA has relocated to the firm’s office in Shanghai, ... and design and to better support regional clients. ...
(Date:8/20/2014)... Sockeye salmon that sprint to spawning grounds through fast-moving ... University of British Columbia scientists. , When salmon encounter ... downstream of dams they must move upstream using ... to sprinting for humans. , "Days after sockeye passed ... dying only a short distance from their spawning grounds," ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that nerves ... and that blocking nerve signals using surgery or Botox ... The study was conducted by the laboratory of Timothy ... PhD, in Norway and is published in today,s issue ... long observed that human and mouse cancers contain a ...
(Date:8/20/2014)... Quincy Bioscience, a Wisconsin-based biotech company, has been ... fastest growing private companies in the nation , for ... Bioscience is honored again to be grouped with the ... Bioscience is manufacturer of Prevagen brand supplements, which contain ... in jellyfish and clinically shown to improve memory. Sales ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2
... public sector undertakings and autonomous bodies will give first ... subsidiaries for purchasing 102 medicines for a period of ... the Cabinet, which met here today, the first preference ... their subsidiaries by state governments in their purchases which ...
... of a single ,family. The disease causes severe anxiety// and ... certain behaviors. It is estimated that close relatives of OCD ... ,Now, new research is shedding new light on ... pattern. And while no one gene "causes" OCD, the research ...
... are considering becoming pregnant could prevent preeclampsia if they ... and following it up// during the first three months ... woman’s blood pressure shoots up dangerously and could prove ... University of Pittsburgh say that this condition could be ...
... dependence and abuse can be moderately improved by various ... may be the best clinicians// can hope for at ... ,One-on-one cognitive behavioral therapy (CBT) is most effective, but ... or improve social problems associated with their marijuana use. ...
... According to a study conducted by Linda Chaudron, M.D., an ... the Medical Center// postpartum depression is a disorder which is ... that the women should be screened for a period of ... up is very much essential as the symptoms, develop throughout ...
... the World Organization for Animal Health (OIE) and the ... called the Global Early Warning and Response// System (GLEWS), ... diseases to humans. ,Dr Bernard Vallat, Director ... point of view, controlling contagious animal diseases in their ...
Cached Medicine News:Health News:Obsessive-Compulsive Disorder Is Familial 2Health News:Obsessive-Compulsive Disorder Is Familial 3Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 3Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 2Health News:Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat 3Health News:Early Diagnosis of Postpartum Depression Is Very Essential Among New Mothers 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: